Science
Experimental Pill Nearly Doubles Survival Time for Advanced Pancreatic Cancer
Clinical trial data shows daraxonrasib extends median survival to 13.2 months compared to 6.7 months for chemotherapy in patients with metastatic pancreatic cancer.
